Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Sonoma Pharmaceuticals FCF Yield % Related Terms
Sonoma Pharmaceuticals FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:O8Z vs YCBD, CVSI, AKAN: FCF Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sonoma Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sonoma Pharmaceuticals FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sonoma Pharmaceuticals's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Sonoma Pharmaceuticals's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sonoma Pharmaceuticals (FRA:O8Z) has a FCF Yield % of -75.60 as of Jul. 29, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Sonoma Pharmaceuticals and its competitors. According to the industry distribution chart, Sonoma Pharmaceuticals ranks #969 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 96.2%.
Is Sonoma Pharmaceuticals' FCF Yield % too high?
Sonoma Pharmaceuticals' current FCF Yield % is -75.60. Based on the distribution chart, Sonoma Pharmaceuticals ranks #969 out of 1007 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sonoma Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Sonoma Pharmaceuticals' FCF Yield % compare to YCBD and CVSI?
According to the Drug Manufacturers industry distribution chart, Sonoma Pharmaceuticals ranks #969 out of 1007 companies for FCF Yield %. This places Sonoma Pharmaceuticals in the lower half of its industry. The industry median FCF Yield % is 0.74. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.74, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Sonoma Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sonoma Pharmaceuticals's current FCF Yield % is -75.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sonoma Pharmaceuticals stock overvalued right now?
Sonoma Pharmaceuticals (FRA:O8Z) has a current FCF Yield % of -75.60. The stock's GF Value™ is €6.04, compared to a current price of €2.72 — trading 55% below its estimated fair value. The current FCF Yield % is -75.60. Sonoma Pharmaceuticals' overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Sonoma Pharmaceuticals (FRA:O8Z), the current FCF Yield % is -75.60 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sonoma Pharmaceuticals (FRA:O8Z) Overvalued in 2026?
Based on GuruFocus' analysis, Sonoma Pharmaceuticals stock appears to be undervalued.
The current stock price of €2.72 is trading 55% below its estimated GF Value™ of €6.04.
Key valuation signals for FRA:O8Z:
FCF Yield %: -75.60
GF Value™: €6.04 vs. price of €2.72 (55% below fair value)
No single metric tells the full story. See the FRA:O8Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
34GF Score
Get the complete analysis for FRA:O8Z
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:O8Z has been successfully added to your 
